Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°æÁ÷ÀåÀü¸³¼±»ý°ËÀÌ À½°æ¹ß±â¿¡ ¹ÌÄ¡´Â ¿µÇâ The Effect of Transrectal Ultrasound Guided Prostate Biopsies on Erectile Function

´ëÇѺñ´¢±â°úÇÐȸÁö 2007³â 48±Ç 4È£ p.416 ~ 421
½É¿µÁø, ¹ÚÈïÀç,
¼Ò¼Ó »ó¼¼Á¤º¸
½É¿µÁø ( Sim Yonug-Jin ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

¹ÚÈïÀç ( Park Heung-Jae ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract


Purpose: The aim of this study was to assess the effects of prostate biopsies on erectile dysfunction.

Materials & Methods: Thirty nine patients who underwent transrectal ultrasonography(TRUS)-guided prostate biopsy between March 2006 and September 2006 were prospectively studied. Erectile dysfunction(ED) was assessed by using the self-administered International Index of Erectile Function(IIEF)-5 at the day of biopsy, and at 1 and 3 months later. The concomitant ED-related systemic disease and medications were recorded. The severity of ED was classified into 5 categories.

Results: The patients¡¯ mean age was 57.6 years(range: 32-74). The median IIEF-5 scores at biopsy and at 1 month and 3 months after biopsy were 15.6, 14.9 and 15.1, respectively(p£¾0.05). At the day of the biopsies, ED was reported by 28 patients(71.79%). Concomitant ED-related systemic disease and/or the use of medications were recorded for 18 patients (46.0%). One month and 3 months after biopsies, ED was reported for 31(79.48%) and 30(76.92%) patients, respectively. At 1 and 3 months later, 3 previously potent(7.69%) patients and 2 previously potent(5.13%) patients reported erectile dysfunction, respectively.

Conclusion: TRUS-guided prostate biopsy did not statistically affect erectile dysfunction. Even so, a prospective analysis with more patients is needed and the risk of acute erectile dysfunction should be discussed with the patients undergoing TRUS. (Korean J Urol 2007;48:416-421)

Å°¿öµå

Prostate;Biopsy;Erectile dysfunction

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS